InsiderTrades.com logo
The Final Frontier
From Porter & Company   |   Ad
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
Here’s the full story for you.

IKT Insider Trading

Insider Ownership Percentage: 14.70%
Insider Buying (Last 12 Months): $198,650.00
Insider Selling (Last 12 Months): $0.00

Inhibikase Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Inhibikase Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibikase Therapeutics Share Price & Price History

Current Price: $2.65
Price Change: ▲ Price Increase of +0.04 (1.53%)
As of 11/5/2024 01:00 AM ET

This chart shows the closing price history over time for IKT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Final Frontier
From Porter & Company   |   Ad
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
Here’s the full story for you.

Inhibikase Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/21/2024Arvind KushDirectorBuy145,000$1.37$198,650.00145,000View SEC Filing Icon  
8/16/2022Milton H. WernerCEOBuy833$4.80$3,998.40889,238View SEC Filing Icon  
5/27/2022Milton H. WernerCEOBuy833$5.88$4,898.04888,405View SEC Filing Icon  
5/20/2022Milton H. WernerCEOBuy1,666$3.60$5,997.60887,572View SEC Filing Icon  
5/19/2022Joseph FrattaroliCFOBuy658$3.84$2,526.728,015View SEC Filing Icon  
11/17/2021Milton H. WernerCEOBuy3,931$11.82$46,464.42View SEC Filing Icon  
See Full Table
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Inhibikase Therapeutics (NYSE:IKT)

3.81% of Inhibikase Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IKT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Inhibikase Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC589,575$0.71M0.0%N/A8.170%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC186,046$0.26M0.0%-62.5%3.477%Search for SEC Filing on Google Icon
9/21/2023Barclays PLC11,455$41K0.0%N/A0.214%Search for SEC Filing on Google Icon
8/8/2023Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266%Search for SEC Filing on Google Icon
5/2/2023Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286%Search for SEC Filing on Google Icon
2/10/2023Blair William & Co. IL229,000$0.11M0.0%+27.9%0.817%Search for SEC Filing on Google Icon
7/12/2022Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259%Search for SEC Filing on Google Icon
5/6/2022Retirement Planning Co of New England Inc.116,402$0.17M0.1%-21.0%0.461%Search for SEC Filing on Google Icon
5/5/2022Lynwood Capital Management Inc.120,000$0.18M0.2%-52.9%0.476%Search for SEC Filing on Google Icon
5/4/2022Hamilton Lane Advisors LLC165,635$0.25M0.1%N/A0.657%Search for SEC Filing on Google Icon
5/3/2022Redmond Asset Management LLC122,682$0.18M0.1%N/A0.486%Search for SEC Filing on Google Icon
2/14/2022Murchinson Ltd.220,947$0.33M0.0%-31.2%0.878%Search for SEC Filing on Google Icon
2/8/2022Retirement Planning Co of New England Inc.147,331$0.22M0.1%N/A0.586%Search for SEC Filing on Google Icon
2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279%Search for SEC Filing on Google Icon
11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202%Search for SEC Filing on Google Icon
8/17/2021Zeke Capital Advisors LLC93,800$0.26M0.0%+398.9%0.926%Search for SEC Filing on Google Icon
8/16/2021Antara Capital LP250,000$0.70M0.0%N/A2.467%Search for SEC Filing on Google Icon
8/16/2021Warberg Asset Management LLC90,000$0.25M0.0%N/A0.888%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP109,749$0.31M0.1%N/A1.083%Search for SEC Filing on Google Icon
8/13/2021Murchinson Ltd.320,947$0.90M0.3%N/A3.167%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644%Search for SEC Filing on Google Icon
8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276%Search for SEC Filing on Google Icon
8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,857$0.11M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More on Inhibikase Therapeutics

Today's Range

Now: $2.65
Low: $2.61
High: $2.71

50 Day Range

MA: $1.61
Low: $1.13
High: $2.77

52 Week Range

Now: $2.65
Low: $0.80
High: $3.82

Volume

100,106 shs

Average Volume

188,030 shs

Market Capitalization

$19.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Who are the company insiders with the largest holdings of Inhibikase Therapeutics?

Inhibikase Therapeutics' top insider investors include:
  1. Arvind Kush (Director)
Learn More about top insider investors at Inhibikase Therapeutics.
The Final Frontier
From Porter & Company   |   Ad
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
Here’s the full story for you.